{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:18:37Z","timestamp":1787635117574,"version":"build-2736575974"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The potential of probiotics and synbiotics as a targeted microbiome intervention for metabolic dysfunction-associated steatotic liver disease (MASLD\/NAFLD) has garnered significant attention; however, their clinical efficacy exhibits substantial heterogeneity. This study aimed to systematically evaluate the clinical efficacy of adjunctive probiotic and synbiotic therapy in MASLD\/NAFLD and explore the sources of this heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted across PubMed, Web of Science, Embase, and The Cochrane Library for randomized controlled trials (RCTs) published up to June 2026. RevMan 5.3 and Stata 17.0 were utilized to pool effect sizes [mean difference (MD)\/standardized mean difference (SMD)]. Subgroup analyses and the GRADE system were employed to investigate heterogeneity and assess the quality of evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 30 RCT publications encompassing 1,516 unique patients were included. The meta-analysis demonstrated that probiotics and synbiotics significantly mitigated liver injury (ALT, AST) and systemic inflammation (TNF-\u03b1), while improving specific metabolic parameters (FPG, TC, HDL-C) (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). Although the overall effects on triglycerides (TG) and insulin resistance (HOMA-IR) were not statistically significant, subgroup analyses revealed more pronounced benefits in glucolipid metabolism among younger populations (&amp;lt;50\u202fyears), Asian cohorts, and those receiving short-to-medium-term interventions (&amp;lt;24\u202fweeks). Furthermore, insulin resistance was significantly ameliorated in non-diabetic MASLD\/NAFLD patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>As an adjunct to lifestyle interventions, probiotics and synbiotics effectively ameliorate liver injury and systemic inflammation in patients with MASLD\/NAFLD. Their regulatory efficacy on lipid metabolism and insulin resistance is significantly influenced by variables including patient age, geographical region, and intervention duration. For younger, non-diabetic MASLD\/NAFLD patients, short-to-medium-term probiotic interventions (&amp;lt;24\u202fweeks) yield optimal metabolic benefits. These findings underscore the necessity of adopting precision microbiome-targeted intervention strategies based on patient stratification in future clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261442665<\/jats:ext-link>\n                      , identifier PROSPERO (CRD420261442665).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1940415","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:22:49Z","timestamp":1787631769000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of probiotics and synbiotics on liver enzymes, glucose and lipid metabolism, and inflammatory markers in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Ying","family":"Jiang","sequence":"first","affiliation":[{"name":"School of Traditional Chinese Medicine, Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Shi","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Cao","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Hunan University of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/hep.32228","article-title":"Global burden of NAFLD and chronic liver disease among adolescents and young adults","volume":"75","author":"Paik","year":"2022","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical Bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"155642","DOI":"10.1016\/j.metabol.2023.155642","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","volume":"146","author":"Golabi","year":"2023","journal-title":"Metabolism"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in Asia, the middle east and north Africa: data from global burden of disease 2009-2019","volume":"75","author":"Golabi","year":"2021","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e40653","DOI":"10.2196\/40653","article-title":"The global prevalence of nonalcoholic fatty liver disease and its association with cancers: systematic review and meta-analysis","volume":"12","author":"Muhamad","year":"2023","journal-title":"Interact J Med Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"9625","DOI":"10.3390\/ijms26199625","article-title":"Diet and lifestyle interventions in metabolic dysfunction-associated fatty liver disease: a comprehensive review","volume":"26","author":"Sheikh","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2223339","DOI":"10.1080\/19490976.2023.2223339","article-title":"Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-plus trial sub analysis","volume":"15","author":"G\u00f3mez-P\u00e9rez","year":"2023","journal-title":"Gut Microbes"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"106507","DOI":"10.1016\/j.phrs.2022.106507","article-title":"Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease","volume":"185","author":"Khanmohammadi","year":"2022","journal-title":"Pharmacol Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/nu17010143","article-title":"Dietary influences on gut microbiota and their role in metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","author":"Hamamah","year":"2024","journal-title":"Nutrients"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.atherosclerosis.2015.01.001","article-title":"A concise review of non-alcoholic fatty liver disease","volume":"239","author":"Than","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41423-020-00580-w","article-title":"Immunopathobiology and therapeutic targets related to cytokines in liver diseases","volume":"18","author":"He","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1093\/advances\/nmy063","article-title":"Mechanisms of action of probiotics","volume":"10","author":"Plaza-Diaz","year":"2019","journal-title":"Adv Nutr"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clnesp.2020.06.020","article-title":"The effects of bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: a randomized, placebo-controlled, clinical trial","volume":"39","author":"Abhari","year":"2020","journal-title":"Clin Nutr ESPEN"},{"key":"ref25","first-page":"1090","article-title":"Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial","volume":"15","author":"Aller","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1362694","DOI":"10.3389\/fnut.2024.1362694","article-title":"Probiotic supplementation for 24\u202fweeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial","volume":"11","author":"Silva-Sperb","year":"2024","journal-title":"Front Nutr"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4103\/2008-7802.178533","article-title":"The effect of symbiotic supplementation on liver enzymes, C-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: a clinical trial","volume":"7","author":"Asgharian","year":"2016","journal-title":"Int J Prev Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/biomedicines11020640","article-title":"The effects of probiotics on small intestinal microbiota composition, inflammatory cytokines and intestinal permeability in patients with non-alcoholic fatty liver disease","volume":"11","author":"Ayob","year":"2023","journal-title":"Biomedicine"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"100769","DOI":"10.1016\/j.aohep.2022.100769","article-title":"Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: a double-blind placebo-controlled randomized study","volume":"28","author":"Barcelos","year":"2023","journal-title":"Ann Hepatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.15171\/mejdd.2017.66","article-title":"Effects of probiotic and prebiotic supplementation on leptin, adiponectin, and glycemic parameters in non-alcoholic fatty liver disease: a randomized clinical trial","volume":"9","author":"Behrouz","year":"2017","journal-title":"Middle East J Dig Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: a randomized clinical trial","volume":"85","author":"Behrouz","year":"2020","journal-title":"J Food Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12876-021-01660-5","article-title":"A randomised placebo controlled trial of VSL#3\u00ae probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease","volume":"21","author":"Chong","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"846873","DOI":"10.3389\/fnut.2022.846873","article-title":"Probiotic therapy with VSL#3\u00ae in patients with NAFLD: a randomized clinical trial","volume":"9","author":"Derosa","year":"2022","journal-title":"Front Nutr"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e000315","DOI":"10.1136\/bmjgast-2019-000315","article-title":"High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study","volume":"6","author":"Duseja","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"278","DOI":"10.17179\/excli2016-846","article-title":"Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease","volume":"16","author":"Ekhlasi","year":"2017","journal-title":"EXCLI J"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.tjnut.2023.05.019","article-title":"Probiotic supplementation, hepatic fibrosis, and the microbiota profile in patients with nonalcoholic steatohepatitis: a randomized controlled trial","volume":"153","author":"Escouto","year":"2023","journal-title":"J Nutr"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s40001-026-03901-3","article-title":"Multi-strain synbiotic and lifestyle modifications on patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a randomized double-blinded placebo-controlled trial","volume":"31","author":"Faghieh Dinavari","year":"2026","journal-title":"Eur J Med Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/nu8070397","article-title":"Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis","volume":"8","author":"Ferolla","year":"2016","journal-title":"Nutrients"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"102083","DOI":"10.1016\/j.cdnut.2024.102083","article-title":"Bacillus coagulans TCI711 supplementation improved nonalcoholic fatty liver by modulating gut microbiota: a randomized, placebo-controlled, clinical trial","volume":"8","author":"Hsieh","year":"2024","journal-title":"Curr Dev Nutr"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5812\/ircmj.46017","article-title":"The effect of probiotic and\/or prebiotic on liver function tests in patients with nonalcoholic fatty liver disease: a double blind randomized clinical trial","volume":"19","author":"Javadi","year":"2024","journal-title":"Iran Red Crescent Med J"},{"key":"ref41","first-page":"131","article-title":"The potential role of probiotics or\/and prebiotic on serum lipid profile and insulin resistance in alcoholic fatty liver disease: a double blind randomized clinical trial","volume":"4","author":"Javadi","year":"2017","journal-title":"Crescent J Med Biol Sci"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.6133\/apjcn.042018.05","article-title":"Pro- and prebiotic effects on oxidative stress and inflammatory markers in non-alcoholic fatty liver disease","volume":"27","author":"Javadi","year":"2018","journal-title":"Asia Pac J Clin Nutr"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e0307181","DOI":"10.1371\/journal.pone.0307181","article-title":"Probiotic lactobacillus fermentum TSF331, lactobacillus reuteri TSR332, and lactobacillus plantarum TSP05 improved liver function and uric acid management-a pilot study","volume":"19","author":"Lin","year":"2024","journal-title":"PLoS One"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/1751-2980.12561","article-title":"Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial","volume":"18","author":"Manzhalii","year":"2017","journal-title":"J Dig Dis"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2478\/rjim-2024-0004","article-title":"The effects of synbiotics on the liver steatosis, inflammation, and gut microbiome of metabolic dysfunction-associated liver disease patients-randomized trial","volume":"62","author":"Mitrovi\u0107","year":"2024","journal-title":"Romanian J Intern Med Rev Roum Med Interne"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.3390\/nu13093192","article-title":"The effect of probiotics (MCP\u00ae BCMC\u00ae strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease","volume":"13","author":"Mohamad Nor","year":"2021","journal-title":"Nutrients"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"7386","DOI":"10.3168\/jds.2014-8500","article-title":"Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease","volume":"97","author":"Nabavi","year":"2014","journal-title":"J Dairy Sci"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"82","DOI":"10.22062\/jkmu.2020.89598","article-title":"The effect of GeriLact on non-alcoholic fatty liver disease","volume":"27","author":"Sadrkabir","year":"2020","journal-title":"J Kerman Univ Med Sci"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3350\/cmh.2018.0006","article-title":"Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease","volume":"24","author":"Sayari","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/07315724.2015.1031355","article-title":"Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial","volume":"35","author":"Sepideh","year":"2016","journal-title":"J Am Coll Nutr"},{"key":"ref52","first-page":"531","article-title":"Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: a double blind randomized clinical trial","volume":"4","author":"Shavakhi","year":"2013","journal-title":"Int J Prev Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12967-025-07478-z","article-title":"The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial","volume":"24","author":"Won","year":"2025","journal-title":"J Transl Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"105454","DOI":"10.1016\/j.fbio.2024.105454","article-title":"The role of probiotics in the treatment of non-alcoholic fatty liver disease (NAFLD): new insights based on meta-analysis and subgroup analysis","volume":"62","author":"Xiao","year":"2024","journal-title":"Food Biosci"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"Endpoints and clinical trial design for nonalcoholic steatohepatitis","volume":"54","author":"Sanyal","year":"2011","journal-title":"Hepatology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/nutrit\/nuad086","article-title":"The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis","volume":"82","author":"Amini-Salehi","year":"2024","journal-title":"Nutr Rev"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/nutrit\/nuy031","article-title":"Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"76","author":"Loman","year":"2018","journal-title":"Nutr Rev"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"6911","DOI":"10.3748\/wjg.v19.i40.6911","article-title":"Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis","volume":"19","author":"Ma","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1484598","DOI":"10.1155\/2019\/1484598","article-title":"Systematic review with meta-analysis: the effects of probiotics in nonalcoholic fatty liver disease","volume":"2019","author":"Xiao","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"e32734","DOI":"10.1097\/MD.0000000000032734","article-title":"Efficacy of probiotics on nonalcoholic fatty liver disease: a meta-analysis","volume":"102","author":"Zhou","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1097\/HJH.0000000000000763","article-title":"Gamma-glutamyltransferase and risk of hypertension: a systematic review and dose-response meta-analysis of prospective evidence","volume":"33","author":"Kunutsor","year":"2015","journal-title":"J Hypertens"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1002\/hep.23593","article-title":"Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham heart study","volume":"51","author":"Speliotes","year":"2010","journal-title":"Hepatology"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1014670","DOI":"10.3389\/fendo.2022.1014670","article-title":"Probiotics for the improvement of metabolic profiles in patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"14691","DOI":"10.1073\/pnas.1005963107","article-title":"Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa","volume":"107","author":"De Filippo","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/MCO.0000000000001235","article-title":"Interactions between nutrition, GLP-1 secretion, and composition of the gut microbiome","volume":"29","author":"Kouraki","year":"2026","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2337\/db06-1491","article-title":"Metabolic endotoxemia initiates obesity and insulin resistance","volume":"56","author":"Cani","year":"2007","journal-title":"Diabetes"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.clnu.2024.04.004","article-title":"Optimal probiotic combinations for treating nonalcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"43","author":"Yang","year":"2024","journal-title":"Clin Nutr"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"107398","DOI":"10.1016\/j.phrs.2024.107398","article-title":"The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: a systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Musazadeh","year":"2024","journal-title":"Pharmacol Res"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1143548","DOI":"10.3389\/fimmu.2023.1143548","article-title":"Probiotics fortify intestinal barrier function: a systematic review and meta-analysis of randomized trials","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Immunol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/MEG.0000000000001371","article-title":"The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis","volume":"31","author":"Khan","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"e21166","DOI":"10.7717\/peerj.21166","article-title":"The efficacy of gut microbiota-regulating drugs on metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis","volume":"14","author":"Wang","year":"2026","journal-title":"PeerJ"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1940415\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:22:51Z","timestamp":1787631771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1940415\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":74,"alternative-id":["10.3389\/fnut.2026.1940415"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1940415","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1940415"}}